Page 166 - ASHG 2012 Annual Meeting Program Guide

POSTER SESSIONS
155
POSTER SESSIONS
W=Wednesday authors will present; T=Thursday authors will present; F=Friday authors will present
X. Qiu, T. Popper, K. Boyd, Q. Kuang, Y.B. Berhane, H.
Henrique, N. Perera, P. Prakruthi, D. Patel, S. Momin, M.
Nakhla, E. Marjan, Z. Chen, D. Cheng, R. Feld, N.B. Leighl,
F.A. Shepherd, M.-S. Tsao, W. Xu, G. Liu, S. Cuffe.
1109
F The PROFILE Study: Genetic prostate cancer
risk stratification for targeted screening.
E. K. Bancroft,
E. C. Castro, N. Taylor, E. Page, E. Saunders, T. Dadaev, A.
Lee, A. Antoniou, Z. Kote-Jarai, R. Eeles.
1110
W Lgr5 expression and its relatedness with
other tumor stem cell markers in human gastric
adenocarcinoma.
W. Fan, Y. W. Guo, Y. Y. Xie, Y.S. Li, W.
Chen.
1111
T The
TP53
16
bp duplication polymorphism is
associated with breast cancer.
M. Gallegos, Jr., A.
Gutiérrez, A. Ramos, E. Salas, J. M. Castro, A. M. Puebla,
L. E. Figuera, G. M. Zúñiga.
1112
F Statistics of cellular evolution in leukemia:
Allelic variations in patient trajectories based on
immune repertoire sequencing.
H. Gao, C. Wang, A.
C. Logan, C. D. Bustamante, J. Seok, D. B. Miklos, R. W.
Davis, M. W. Feldman, W. Xiao.
1113
W Genetic polymorphisms and colorectal cancer
risk: A systematic review of meta-analyses.
B. Haerian,
M. Haerian.
1114
T NRF2 and sulfiredoxin genetic polymorphisms
and protein expression predict outcome in breast
cancer.
J. M. Hartikainen, M. Tengström, V.-M. Kosma, V.
Kinnula, A. Mannermaa, Y. Soini.
1115
F Complex tumor genomes inferred from plasma-
DNA and circulating tumor cells of patients with
cancer.
E. Heitzer, M. Auer, E. M. Hoffmann, C. Beneken,
M. Pichler, P. Ulz, S. Lax, J. Waldispuehl-Geigl, O.
Mauermann, G. Pristauz, C. Lackner, G. Höfler, F. Eisner,
E. Petru, H. Sill, H. Samonigg, K. Pantel, S. Riethdorf, T.
Bauernhofer, J. B. Geigl, M. R. Speicher.
1116
W Novel integrative genomics approach for
associating GWAS information with triple negative
breast cancer.
C. Hicks, K. Backus, A. Pannuti, L. Miele.
1117
T Germline variation in TP53 regulatory network
genes associates with breast cancer survival and
treatment outcome.
M. Jamshidi, M. K. Schmidt, T. Dörk,
M. Garcia-Closas, T. Heikkinen, S. Cornelissen, S. van
den Broek, P. Schürmann, A. Meyer, T. W. Park-Simon,
J. Figueroa, M. Sherman, J. Lissowska, G. T. Keong,
A. Irwanto, M. Laakso, S. Hautaniemi, K. Aittomäki, C.
Blomqvist, J. Liu, H. Nevanlinna.
1118
F Detection of
FLT3
internal tandem duplication
and D835 mutations in Iranian patients with acute
myeloid leukemia.
L. Kokabee, A. Ahmadzadeh, M.
Kokabee, M. Karimipoor.
1119
W Association of gastric cancer with Amerindian
ancestry, socioeconomic and nutritional factors and
a gene candidate study in a Latin American admixed
population.
L. Lacorte, R. Zamudio, G. Soares-Souza,
1096
T rs28381943 and rs2032586 SNPs of
ABCB1
gene may be the reason of mRNA stabilization which
may lead to gene overexpression.
M. S. Shahbazi,
M. M. Mansoori, M. G. Golalipour, S. A. Alizadeh, A. J.
Jahangirerad, A. T. Tahmasebifar, S. R. K. Khanduzi.
1097
F Identification and functional characterization of
a novel splicing form of the
TPCN2 gene
on 11q13.3
within a region associated with prostate cancer
risk.
N. Sikdar, C. Chung, J. Fang, M. Tarway, W. Tang,
S. Mukherjee Dey, S. Ambs, L. Prokunina-Olsson, S.
Chanock.
1098
W An integrated analysis of genomic variation
and transcriptome sequencing to identify novel
susceptibility genes for breast cancer.
E. Wagner, S.
Clare, M. Radovich, Y. Liu, B. Schneider, A. M. Storniolo,
C. He.
1099
T Effects of breast cancer associated
PALB2
c.1592delT founder mutation at the cellular level.
R. Winqvist, J. Nikkilä, K. Pylkäs, H. Peltoketo, B. Xia, H.
Pospiech.
1100
F Global correlation of expression with prostate
cancer associated variants identifies IRX4 as a
prostate cancer expression trait locus.
X. Xu, W. M.
Hussain, N. Kitabayashi, M. A. Rubin, F. Demichelis, R. J.
Klein.
1101
W Interplay of tumor suppressor genes and
oncogenes in ovarian cancer.
M. Zhao, S. Sun, Z. Zhao.
1102
T Establishment of breast, leiomyosarcoma
and thyroid cancer stem cells derived from carriers
of p.R337H
TP53
germline mutation within one Li-
Fraumeni syndrome family.
L. I. Mambelli, I. Kerkis, F.
Fortes, P. Hainaut, M. I. W. Achatz.
1103
F Functional validation using eQTL needs cell-
specific approaches.
S. Kim, H.-H. Won, J.-W. Kim, D. H.
Kim, S.-T. Lee, S. Kim, S.-H. Kim, C. W. Jung.
1104
W Functional characterization of HLA allelotypes
associated with follicular lymphoma risk.
F. C. M. Sillé,
L. Conde, C. F. Skibola.
1105
T microRNA expression for classification of
histiocytic sarcomas in dogs.
J. Aguirre Hernandez, J. M.
Dobson, T. M. Hoather, D. R. Sargan, F. Constantino-Casas.
1106
F Molecular urine assay of
PCA3, MMP2, MMP9
and
KLK3
in men with prostate cancer and benign
prostatic hyperplasia.
H. Akin, A. Simsir, F. Hazan, T. R.
Ozdemir, I. Cureklibatir, G. Itirli, C. Gunduz, C. Ozkinay, F.
Ozkinay.
1107
W The effect of copy number variation in the
phase II detoxification genes,
UGT2B17
and
UGT2B28
,
on colorectal cancer risk.
A. Y. Angstadt, A. S. Berg, J.
Zhu, P. Miller, T. J. Hartman, S. M. Lesko, J. E. Muscat, P.
Lazarus, C. J. Gallagher.
1108
T Genetic sequence variant in microRNA genes
and survival in non-small cell lung cancer.
A.K. Azad,